OBJECTIVES: DUPIXAM was an SNDS (exhaustive French claims database) study conducted between 2019 and 2020 to characterize adult patients treated with dupilumab for moderate-to-severe atopic dermatitis (AD) and assess their therapeutic pathway before initiating a treatment with dupilumab.

METHODS: The patients identified with ≥1 dupilumab 300mg delivery for moderate-to-severe AD, were characterized through their demographics, comorbidities, concomitant treatments, as well as previous therapeutic journey: topicals and systemic treatments delivered to treat moderate-to-severe AD, inpatient and outpatient consults.

RESULTS: Among the 3,216 patients identified who initiated a treatment with dupilumab between March 2019 and December 2020 for moderate-to-severe AD, 52.8% were male and aged 45.2 ± 19.4, whereas female patients were aged 40.2 ± 17.6. Healthcare data history was ≥8 years for 3,134 (97.4%) patients, with a maximum history of 10 years. Regarding their AD therapeutic journey, 3,204 (99.7%) had previously been treated with topical agents and 3,050 (94.8%) with a systemic treatment, including 1,542 (47.9%) with cyclosporine and 464 (14.4%) with methotrexate. These patients had consulted their dermatologist on average 3 times the previous year and among them, 960 (29.9%) had been hospitalized at least once for AD in the previous 10 years. 925 (28.8%) patients presented signs of severe asthma, 598 (18.6%) had received treatments for high blood pressure, 422 (13.7%) had diabetes, and 490 (15.7%) were affected with peripheral vascular disorders; in total, 894 (27.8%) patients had a Charlson index ≥1. It was also observed that patients who initiated a treatment with dupilumab without previously receiving cyclosporine tended to be older and presented more comorbidities and/or had already received a treatment with methotrexate.

CONCLUSIONS: With 2,451 (78.2%) patients who had a history of AD ≥ 8 years, DUPIXAM was the first study to profile exhaustively French patients with moderate-to-severe AD who were treated with a biologic agent.